vs
AMC ENTERTAINMENT HOLDINGS, INC.（AMC）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
AMC ENTERTAINMENT HOLDINGS, INC.的季度营收约是Revvity的1.7倍（$1.3B vs $772.1M），Revvity净利率更高（12.7% vs -9.9%，领先22.6%），Revvity同比增速更快（5.9% vs -1.4%），Revvity自由现金流更多（$161.8M vs $43.3M），过去两年AMC ENTERTAINMENT HOLDINGS, INC.的营收复合增速更高（16.4% vs 9.0%）
AMC娱乐控股是总部位于美国堪萨斯州利伍德的连锁影院集团，1920年创立于密苏里州堪萨斯城，是全球规模最大的影院运营商，目前在全球共运营约860家影院、总计超过9600块银幕，业务覆盖美国与欧洲多地。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
AMC vs RVTY — 直观对比
营收规模更大
AMC
是对方的1.7倍
$772.1M
营收增速更快
RVTY
高出7.2%
-1.4%
净利率更高
RVTY
高出22.6%
-9.9%
自由现金流更多
RVTY
多$118.5M
$43.3M
两年增速更快
AMC
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $772.1M |
| 净利润 | $-127.4M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 0.0% | 14.5% |
| 净利率 | -9.9% | 12.7% |
| 营收同比 | -1.4% | 5.9% |
| 净利润同比 | 6.0% | 3.9% |
| 每股收益（稀释后） | $-0.28 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMCRVTY
| Q4 25 | $1.3B | $772.1M | ||
| Q3 25 | $1.3B | $698.9M | ||
| Q2 25 | $1.4B | $720.3M | ||
| Q1 25 | $862.5M | $664.8M | ||
| Q4 24 | $1.3B | $729.4M | ||
| Q3 24 | $1.3B | $684.0M | ||
| Q2 24 | $1.0B | $691.7M | ||
| Q1 24 | $951.4M | $649.9M |
净利润AMCRVTY
| Q4 25 | $-127.4M | $98.4M | ||
| Q3 25 | $-298.2M | $46.7M | ||
| Q2 25 | $-4.7M | $53.9M | ||
| Q1 25 | $-202.1M | $42.2M | ||
| Q4 24 | $-135.6M | $94.6M | ||
| Q3 24 | $-20.7M | $94.4M | ||
| Q2 24 | $-32.8M | $55.4M | ||
| Q1 24 | $-163.5M | $26.0M |
毛利率AMCRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率AMCRVTY
| Q4 25 | 0.0% | 14.5% | ||
| Q3 25 | 2.8% | 11.7% | ||
| Q2 25 | 6.6% | 12.6% | ||
| Q1 25 | -16.9% | 10.9% | ||
| Q4 24 | 0.4% | 16.3% | ||
| Q3 24 | 5.3% | 14.3% | ||
| Q2 24 | -4.6% | 12.4% | ||
| Q1 24 | -11.4% | 6.8% |
净利率AMCRVTY
| Q4 25 | -9.9% | 12.7% | ||
| Q3 25 | -22.9% | 6.7% | ||
| Q2 25 | -0.3% | 7.5% | ||
| Q1 25 | -23.4% | 6.4% | ||
| Q4 24 | -10.4% | 13.0% | ||
| Q3 24 | -1.5% | 13.8% | ||
| Q2 24 | -3.2% | 8.0% | ||
| Q1 24 | -17.2% | 4.0% |
每股收益（稀释后）AMCRVTY
| Q4 25 | $-0.28 | $0.86 | ||
| Q3 25 | $-0.58 | $0.40 | ||
| Q2 25 | $-0.01 | $0.46 | ||
| Q1 25 | $-0.47 | $0.35 | ||
| Q4 24 | $-0.28 | $0.77 | ||
| Q3 24 | $-0.06 | $0.77 | ||
| Q2 24 | $-0.10 | $0.45 | ||
| Q1 24 | $-0.62 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $428.5M | $919.9M |
| 总债务越低越好 | $4.0B | — |
| 股东权益账面价值 | $-1.9B | $7.3B |
| 总资产 | $8.0B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMCRVTY
| Q4 25 | $428.5M | $919.9M | ||
| Q3 25 | $365.8M | $931.4M | ||
| Q2 25 | $423.7M | $991.8M | ||
| Q1 25 | $378.7M | $1.1B | ||
| Q4 24 | $632.3M | $1.2B | ||
| Q3 24 | $527.4M | $1.2B | ||
| Q2 24 | $770.3M | $2.0B | ||
| Q1 24 | $624.2M | $1.7B |
总债务AMCRVTY
| Q4 25 | $4.0B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $4.1B | — | ||
| Q4 24 | $4.1B | — | ||
| Q3 24 | $4.2B | — | ||
| Q2 24 | $4.3B | — | ||
| Q1 24 | $4.5B | — |
股东权益AMCRVTY
| Q4 25 | $-1.9B | $7.3B | ||
| Q3 25 | $-1.8B | $7.4B | ||
| Q2 25 | $-1.7B | $7.6B | ||
| Q1 25 | $-1.7B | $7.6B | ||
| Q4 24 | $-1.8B | $7.7B | ||
| Q3 24 | $-1.7B | $7.9B | ||
| Q2 24 | $-1.7B | $7.9B | ||
| Q1 24 | $-2.0B | $7.8B |
总资产AMCRVTY
| Q4 25 | $8.0B | $12.2B | ||
| Q3 25 | $8.0B | $12.1B | ||
| Q2 25 | $8.2B | $12.4B | ||
| Q1 25 | $8.1B | $12.4B | ||
| Q4 24 | $8.2B | $12.4B | ||
| Q3 24 | $8.3B | $12.8B | ||
| Q2 24 | $8.6B | $13.4B | ||
| Q1 24 | $8.5B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $126.7M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $43.3M | $161.8M |
| 自由现金流率自由现金流/营收 | 3.4% | 21.0% |
| 资本支出强度资本支出/营收 | 6.5% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $-365.9M | $509.4M |
8季度趋势，按日历期对齐
经营现金流AMCRVTY
| Q4 25 | $126.7M | $182.0M | ||
| Q3 25 | $-14.9M | $138.5M | ||
| Q2 25 | $138.4M | $134.3M | ||
| Q1 25 | $-370.0M | $128.2M | ||
| Q4 24 | $203.6M | $174.2M | ||
| Q3 24 | $-31.5M | $147.9M | ||
| Q2 24 | $-34.6M | $158.6M | ||
| Q1 24 | $-188.3M | $147.6M |
自由现金流AMCRVTY
| Q4 25 | $43.3M | $161.8M | ||
| Q3 25 | $-81.1M | $120.0M | ||
| Q2 25 | $88.9M | $115.5M | ||
| Q1 25 | $-417.0M | $112.2M | ||
| Q4 24 | $113.9M | $149.8M | ||
| Q3 24 | $-92.2M | $125.6M | ||
| Q2 24 | $-79.2M | $136.6M | ||
| Q1 24 | $-238.8M | $129.7M |
自由现金流率AMCRVTY
| Q4 25 | 3.4% | 21.0% | ||
| Q3 25 | -6.2% | 17.2% | ||
| Q2 25 | 6.4% | 16.0% | ||
| Q1 25 | -48.3% | 16.9% | ||
| Q4 24 | 8.7% | 20.5% | ||
| Q3 24 | -6.8% | 18.4% | ||
| Q2 24 | -7.7% | 19.7% | ||
| Q1 24 | -25.1% | 20.0% |
资本支出强度AMCRVTY
| Q4 25 | 6.5% | 2.6% | ||
| Q3 25 | 5.1% | 2.6% | ||
| Q2 25 | 3.5% | 2.6% | ||
| Q1 25 | 5.4% | 2.4% | ||
| Q4 24 | 6.9% | 3.4% | ||
| Q3 24 | 4.5% | 3.3% | ||
| Q2 24 | 4.3% | 3.2% | ||
| Q1 24 | 5.3% | 2.7% |
现金转化率AMCRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMC
| Admission | $701.6M | 54% |
| Food And Beverage | $436.5M | 34% |
| Other | $106.2M | 8% |
| Advertising | $44.0M | 3% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
